Organon (OGN) Non-Current Debt (2021 - 2026)
Organon (OGN) recorded quarterly Non-Current Debt of $8.6 billion in Q1 2026, down 0.87% quarter-over-quarter from $8.6 billion in Q4 2025, and down 4.29% on a YoY basis from $8.9 billion in Q1 2025.
Organon (OGN) Non-Current Debt (2021 - 2026) Analysis & Trends
Organon's Non-Current Debt history runs 6 years deep, the most recent figure standing at $8.6 billion for Q1 2026.
- In Q1 2026, Non-Current Debt fell 4.29% year-over-year to $8.6 billion; the TTM figure through Mar 2026 stood at $8.6 billion (down 4.29% YoY), while the FY2025 annual figure was $8.6 billion, down 2.62% from the prior year.
- Non-Current Debt was $8.6 billion for Q1 2026 at Organon, down from $8.6 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $9.1 billion in Q1 2022 to a low of $8.6 billion in Q1 2026.
- Historically, Non-Current Debt has averaged $8.8 billion across 5 years, with a median of $8.7 billion in 2024.
- The sharpest annual moves came in 2022 and 2025: Non-Current Debt decreased 6.13% in 2022, then increased 2.65% in 2025.
- A 5-year view of Non-Current Debt shows it stood at $8.9 billion in 2022, then slipped by 1.73% to $8.8 billion in 2023, then gained by 1.25% to $8.9 billion in 2024, then fell by 2.62% to $8.6 billion in 2025, then dropped by 0.87% to $8.6 billion in 2026.
- The last three Non-Current Debt figures came in at $8.6 billion (Q1 2026), $8.6 billion (Q4 2025), and $8.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | -18.89 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 39.37 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 37.53 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 42.15 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 8.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.55 Bn |
| Mar 31, 2026 | 8.55 Bn |
| Dec 31, 2025 | 8.63 Bn |
| Dec 31, 2025 | 8.63 Bn |
| Sep 30, 2025 | 8.78 Bn |
| Sep 30, 2025 | 8.78 Bn |
| Jun 30, 2025 | 8.78 Bn |
| Jun 30, 2025 | 8.78 Bn |
| Mar 31, 2025 | 8.94 Bn |
| Mar 31, 2025 | 8.94 Bn |
| Dec 31, 2024 | 8.86 Bn |
| Dec 31, 2024 | 8.86 Bn |
| Sep 30, 2024 | 8.74 Bn |
| Sep 30, 2024 | 8.74 Bn |
| Jun 30, 2024 | 8.65 Bn |
| Jun 30, 2024 | 8.65 Bn |
| Mar 31, 2024 | 8.71 Bn |
| Mar 31, 2024 | 8.71 Bn |
| Dec 31, 2023 | 8.75 Bn |
| Dec 31, 2023 | 8.75 Bn |